[{"id":"78abffa2-7b4c-493d-a391-404776dd9c0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01038778","created_at":"2021-01-18T04:04:38.458Z","updated_at":"2025-02-25T16:58:23.955Z","phase":"Phase 1/2","brief_title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","source_id_and_acronym":"NCT01038778","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR","pipe":"","alterations":" ","tags":["mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 10/29/2009","start_date":" 10/29/2009","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 07/30/2025","study_completion_date":" 07/30/2025","last_update_posted":"2025-02-03"},{"id":"facca190-15a5-41db-a54e-ca426babdb55","acronym":"CABOSUN II","url":"https://clinicaltrials.gov/study/NCT03541902","created_at":"2021-01-18T17:25:42.722Z","updated_at":"2024-07-02T16:34:36.884Z","phase":"Phase 2","brief_title":"Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma","source_id_and_acronym":"NCT03541902 - CABOSUN II","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" mTOR","pipe":"","alterations":" ","tags":["mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Cabometyx (cabozantinib tablet)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/15/2018","start_date":" 05/15/2018","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-06-10"},{"id":"0300bd11-3c88-4727-a08a-0abd664e0d55","acronym":"","url":"https://clinicaltrials.gov/study/NCT05773326","created_at":"2023-03-17T14:02:34.285Z","updated_at":"2024-07-02T16:35:02.449Z","phase":"Phase 1","brief_title":"Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG","source_id_and_acronym":"NCT05773326","lead_sponsor":"Nader Sanai","biomarkers":" PIK3CA • PTEN • mTOR • PIK3R1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation","tags":["PIK3CA • PTEN • mTOR • PIK3R1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2024-05-21"},{"id":"d7d6598c-31e5-4bc3-b406-5e9ff144fe1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03834740","created_at":"2021-01-18T18:56:01.539Z","updated_at":"2024-07-02T16:35:04.374Z","phase":"Phase 1","brief_title":"A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection","source_id_and_acronym":"NCT03834740","lead_sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","biomarkers":" PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression","tags":["PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 02/18/2022","primary_completion_date":" 02/18/2022","study_txt":" Completion: 02/18/2022","study_completion_date":" 02/18/2022","last_update_posted":"2024-05-10"},{"id":"2638658d-5de1-4c1e-afa0-e9fef20584a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01327781","created_at":"2021-01-18T05:24:42.319Z","updated_at":"2024-07-02T16:35:17.724Z","phase":"Phase 1","brief_title":"Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT01327781","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2 • ER • PGR • AKT1 • mTOR • IGF1R • NCOA3 • PI3K","pipe":" | ","alterations":" ER positive • HER-2 expression • EGFR expression","tags":["EGFR • HER-2 • ER • PGR • AKT1 • mTOR • IGF1R • NCOA3 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 expression • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zonalta (Z-endoxifen hydrochloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 03/25/2011","start_date":" 03/25/2011","primary_txt":" Primary completion: 03/05/2017","primary_completion_date":" 03/05/2017","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2024-02-26"},{"id":"8ed50152-7445-409e-9234-a5c457af5345","acronym":"DCLNF1","url":"https://clinicaltrials.gov/study/NCT02332902","created_at":"2023-12-20T20:17:40.463Z","updated_at":"2024-07-02T16:35:25.728Z","phase":"Phase 2","brief_title":"Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T","source_id_and_acronym":"NCT02332902 - DCLNF1","lead_sponsor":"The University of Texas Health Science Center, Houston","biomarkers":" PTEN • mTOR","pipe":"","alterations":" ","tags":["PTEN • mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 03/01/2016","study_completion_date":" 03/01/2016","last_update_posted":"2023-12-20"},{"id":"ed87f07f-d94b-4782-87e1-520859d6cee3","acronym":"GERTRUDE","url":"https://clinicaltrials.gov/study/NCT05933395","created_at":"2023-07-06T16:10:21.285Z","updated_at":"2024-07-02T16:35:31.527Z","phase":"Phase 2","brief_title":"Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor","source_id_and_acronym":"NCT05933395 - GERTRUDE","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" HER-2 • PIK3CA • PTEN • RB1 • AKT1 • mTOR • CDK4","pipe":"","alterations":" ","tags":["HER-2 • PIK3CA • PTEN • RB1 • AKT1 • mTOR • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Nerlynx (neratinib) • Piqray (alpelisib) • Verzenio (abemaciclib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 10/01/2030","primary_completion_date":" 10/01/2030","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2023-10-26"},{"id":"31829fe8-d30b-437f-95cb-00ae52e87483","acronym":"","url":"https://clinicaltrials.gov/study/NCT02049047","created_at":"2021-01-17T17:29:43.082Z","updated_at":"2024-07-02T16:36:04.172Z","phase":"Phase 2","brief_title":"Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy","source_id_and_acronym":"NCT02049047","lead_sponsor":"Armando Santoro, MD","biomarkers":" PTEN • mTOR","pipe":"","alterations":" ","tags":["PTEN • mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 02/01/2011","start_date":" 02/01/2011","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2022-09-10"},{"id":"a041e75d-dea4-42aa-90f8-c25cae180d4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05054166","created_at":"2021-09-23T17:52:59.544Z","updated_at":"2024-07-02T16:36:24.082Z","phase":"","brief_title":"Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study","source_id_and_acronym":"NCT05054166","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" HER-2 • mTOR • PI3K","pipe":" | ","alterations":" HER-2 negative • MTOR mutation","tags":["HER-2 • mTOR • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/30/2021","study_completion_date":" 08/30/2021","last_update_posted":"2021-09-23"},{"id":"81732a4f-3390-49ea-a156-28fdbac06dce","acronym":"","url":"https://clinicaltrials.gov/study/NCT02133742","created_at":"2021-01-18T09:54:06.406Z","updated_at":"2024-07-02T16:36:27.343Z","phase":"Phase 1b","brief_title":"A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer","source_id_and_acronym":"NCT02133742","lead_sponsor":"Pfizer","biomarkers":" PD-L1 • mTOR • KDR • CXCL8 • FLT1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • mTOR • KDR • CXCL8 • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • axitinib"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 09/16/2014","start_date":" 09/16/2014","primary_txt":" Primary completion: 03/31/2017","primary_completion_date":" 03/31/2017","study_txt":" Completion: 07/03/2019","study_completion_date":" 07/03/2019","last_update_posted":"2021-07-28"},{"id":"2c505dcd-09e5-4284-9e05-a7a8505e815b","acronym":"FENET-2016","url":"https://clinicaltrials.gov/study/NCT04790708","created_at":"2021-03-10T12:54:51.502Z","updated_at":"2024-07-02T16:36:33.460Z","phase":"","brief_title":"Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)","source_id_and_acronym":"NCT04790708 - FENET-2016","lead_sponsor":"University Hospital of Ferrara","biomarkers":" mTOR • SSTR • UBR5","pipe":" | ","alterations":" SSTR Expression","tags":["mTOR • SSTR • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/02/2018","start_date":" 07/02/2018","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2021-03-10"},{"id":"c6482f62-b29d-422c-ac88-2950e4e5187d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00827359","created_at":"2021-01-18T03:08:51.503Z","updated_at":"2025-02-25T15:49:51.116Z","phase":"Phase 2","brief_title":"Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT00827359","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" mTOR • PI3K","pipe":" | ","alterations":" MTOR mutation","tags":["mTOR • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2009","start_date":" 03/01/2009","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2021-02-24"},{"id":"9e574470-b55c-4fb9-ba76-d1930189d237","acronym":"KCSG-BR18-13","url":"https://clinicaltrials.gov/study/NCT03698383","created_at":"2021-01-18T18:07:34.589Z","updated_at":"2024-07-02T16:36:34.376Z","phase":"Phase 2","brief_title":"Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT03698383 - KCSG-BR18-13","lead_sponsor":"Korean Cancer Study Group","biomarkers":" PIK3CA • PTEN • mTOR","pipe":" | ","alterations":" HER-2 positive • PIK3CA mutation • MTOR mutation","tags":["PIK3CA • PTEN • mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PIK3CA mutation • MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gedatolisib (PF-05212384) • Herzuma (trastuzumab-pkrb)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/03/2019","start_date":" 12/03/2019","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-02-18"},{"id":"5541a216-9486-47e6-b7bc-94281e26cf3a","acronym":"RESUNET","url":"https://clinicaltrials.gov/study/NCT02713763","created_at":"2021-01-18T13:16:13.508Z","updated_at":"2024-07-02T16:36:49.215Z","phase":"Phase 2","brief_title":"Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib","source_id_and_acronym":"NCT02713763 - RESUNET","lead_sponsor":"Grupo Espanol de Tumores Neuroendocrinos","biomarkers":" mTOR","pipe":"","alterations":" ","tags":["mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 02/14/2017","start_date":" 02/14/2017","primary_txt":" Primary completion: 10/23/2019","primary_completion_date":" 10/23/2019","study_txt":" Completion: 10/23/2019","study_completion_date":" 10/23/2019","last_update_posted":"2020-03-04"},{"id":"f036c2b2-da87-41ef-bd33-09e033f853e5","acronym":"TORCMEK","url":"https://clinicaltrials.gov/study/NCT02583542","created_at":"2021-01-18T12:31:58.659Z","updated_at":"2025-02-25T15:06:51.572Z","phase":"Phase 1/2","brief_title":"A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers","source_id_and_acronym":"NCT02583542 - TORCMEK","lead_sponsor":"Queen Mary University of London","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • PIK3CA • MET • NRAS • PTEN • STK11 • NF1 • FGFR • mTOR","pipe":"","alterations":" ","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • PIK3CA • MET • NRAS • PTEN • STK11 • NF1 • FGFR • mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Koselugo (selumetinib) • sirolimus • vistusertib (AZD2014)"],"overall_status":"Unknown status","enrollment":" Enrollment 118","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2020-02-25"},{"id":"1143e6ad-4fb3-4eac-a9d3-83858e654c43","acronym":"","url":"https://clinicaltrials.gov/study/NCT01614795","created_at":"2021-01-18T06:55:05.325Z","updated_at":"2024-07-02T16:37:04.745Z","phase":"Phase 2","brief_title":"Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma","source_id_and_acronym":"NCT01614795","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR • IR","pipe":"","alterations":" ","tags":["mTOR • IR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 06/18/2012","start_date":" 06/18/2012","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2018-12-11"},{"id":"67594d86-d6cf-4b01-aefe-6548477c2d62","acronym":"EMR100018-001","url":"https://clinicaltrials.gov/study/NCT01971515","created_at":"2021-01-18T08:58:11.943Z","updated_at":"2024-07-02T16:37:06.726Z","phase":"Phase 1","brief_title":"First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies","source_id_and_acronym":"NCT01971515 - EMR100018-001","lead_sponsor":"EMD Serono","biomarkers":" HER-2 • ER • PIK3CA • PGR • PTEN • AKT1 • mTOR • TSC2 • TSC1 • AKT2","pipe":" | ","alterations":" HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PIK3CA • PGR • PTEN • AKT1 • mTOR • TSC2 • TSC1 • AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • rupitasertib (DIACC3010)"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 12/13/2013","start_date":" 12/13/2013","primary_txt":" Primary completion: 08/09/2018","primary_completion_date":" 08/09/2018","study_txt":" Completion: 08/09/2018","study_completion_date":" 08/09/2018","last_update_posted":"2018-09-19"},{"id":"df5c8919-859e-495f-ad58-6796f47c9ac2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03347994","created_at":"2021-01-18T16:32:01.345Z","updated_at":"2024-07-02T16:37:13.268Z","phase":"Phase 1","brief_title":"Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03347994","lead_sponsor":"Justin Watts","biomarkers":" mTOR","pipe":"","alterations":" ","tags":["mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e minnelide"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2018-03-06"},{"id":"efdda097-1fd3-4a61-b2ea-cedf4ab9eb9c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00401778","created_at":"2021-01-18T01:24:22.720Z","updated_at":"2024-07-02T16:37:26.949Z","phase":"Phase 1","brief_title":"Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT00401778","lead_sponsor":"Emory University","biomarkers":" mTOR","pipe":"","alterations":" ","tags":["mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 11/01/2006","start_date":" 11/01/2006","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2016-12-21"}]